CY1107143T1 - Χρηση του et743 στην συνδυαστικη θεραπεια με δεξαμεθαζονη για την θεραπευτικη αγωγη του καρκινου - Google Patents

Χρηση του et743 στην συνδυαστικη θεραπεια με δεξαμεθαζονη για την θεραπευτικη αγωγη του καρκινου

Info

Publication number
CY1107143T1
CY1107143T1 CY20081100059T CY081100059T CY1107143T1 CY 1107143 T1 CY1107143 T1 CY 1107143T1 CY 20081100059 T CY20081100059 T CY 20081100059T CY 081100059 T CY081100059 T CY 081100059T CY 1107143 T1 CY1107143 T1 CY 1107143T1
Authority
CY
Cyprus
Prior art keywords
cancer
dexamethazone
combination therapy
therapeutic treatment
treat
Prior art date
Application number
CY20081100059T
Other languages
English (en)
Inventor
Esteban Cvitkovic
George Daniel Demetri
Cecilia Guzman
Jose Jimeno
Luis Lopez Lazaro
Jean-Louis Misset
Chris Twelves
Daniel D. Von Hoff
Original Assignee
Pharma Mar, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9911183.3A external-priority patent/GB9911183D0/en
Priority claimed from GBGB9911346.6A external-priority patent/GB9911346D0/en
Priority claimed from GBGB9918534.0A external-priority patent/GB9918534D0/en
Priority claimed from GBGB9927005.0A external-priority patent/GB9927005D0/en
Priority claimed from GBGB9927106.6A external-priority patent/GB9927106D0/en
Priority claimed from GB0007637A external-priority patent/GB0007637D0/en
Application filed by Pharma Mar, S.A. filed Critical Pharma Mar, S.A.
Publication of CY1107143T1 publication Critical patent/CY1107143T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Το ΕΤ743 χρησιμοποιείται στην παρασκευή φαρμάκου για την θεραπευτική αγωγή του ανθρώπινου σώματος κατά του καρκίνου.
CY20081100059T 1999-05-13 2008-01-16 Χρηση του et743 στην συνδυαστικη θεραπεια με δεξαμεθαζονη για την θεραπευτικη αγωγη του καρκινου CY1107143T1 (el)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9911183.3A GB9911183D0 (en) 1999-05-13 1999-05-13 Treatment of cancers
GBGB9911346.6A GB9911346D0 (en) 1999-05-14 1999-05-14 Treatment of cancers
GBGB9918534.0A GB9918534D0 (en) 1999-08-05 1999-08-05 Treatment of cancers
GBGB9927005.0A GB9927005D0 (en) 1999-11-15 1999-11-15 Treatment of cancers
GBGB9927106.6A GB9927106D0 (en) 1999-11-16 1999-11-16 Cancer treatment
GB0007637A GB0007637D0 (en) 2000-03-29 2000-03-29 Antitumour compound
EP00927584A EP1176964B8 (en) 1999-05-13 2000-05-15 Uses of et743 for treating cancer

Publications (1)

Publication Number Publication Date
CY1107143T1 true CY1107143T1 (el) 2010-07-28

Family

ID=27546594

Family Applications (4)

Application Number Title Priority Date Filing Date
CY20061101734T CY1105818T1 (el) 1999-05-13 2006-11-30 Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου
CY20081100059T CY1107143T1 (el) 1999-05-13 2008-01-16 Χρηση του et743 στην συνδυαστικη θεραπεια με δεξαμεθαζονη για την θεραπευτικη αγωγη του καρκινου
CY200800007C CY2008007I2 (el) 1999-05-13 2008-04-07 Χρηση του et743 στην συνδυαστικη θεραπεια με δεξαμεθαζονη για την θεραπευτικη αγωγη του καρκινου
CY20111100545T CY1112753T1 (el) 1999-05-13 2011-06-08 Θεραπευτικη αγωγη καρκινων του ανθρωπινου σωματος με τη χρηση toy ετ743

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20061101734T CY1105818T1 (el) 1999-05-13 2006-11-30 Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY200800007C CY2008007I2 (el) 1999-05-13 2008-04-07 Χρηση του et743 στην συνδυαστικη θεραπεια με δεξαμεθαζονη για την θεραπευτικη αγωγη του καρκινου
CY20111100545T CY1112753T1 (el) 1999-05-13 2011-06-08 Θεραπευτικη αγωγη καρκινων του ανθρωπινου σωματος με τη χρηση toy ετ743

Country Status (32)

Country Link
US (1) US8119638B2 (el)
EP (3) EP1716853B9 (el)
JP (2) JP2002544231A (el)
KR (1) KR20020019914A (el)
CN (2) CN1360503A (el)
AR (1) AR028476A1 (el)
AT (3) ATE375795T1 (el)
AU (2) AU777417B2 (el)
BG (1) BG65680B1 (el)
BR (1) BR0010531A (el)
CA (1) CA2373794C (el)
CY (4) CY1105818T1 (el)
CZ (1) CZ301482B6 (el)
DE (4) DE60030554T8 (el)
DK (3) DK1176964T3 (el)
ES (2) ES2294756T3 (el)
FR (1) FR08C0013I2 (el)
HU (2) HU229866B1 (el)
IL (2) IL146434A0 (el)
LU (1) LU91418I2 (el)
MX (1) MXPA01011562A (el)
MY (1) MY164077A (el)
NL (1) NL300337I2 (el)
NO (2) NO324564B1 (el)
NZ (1) NZ515423A (el)
PL (1) PL198185B1 (el)
PT (3) PT1702618E (el)
SI (3) SI1716853T1 (el)
SK (1) SK287580B6 (el)
TR (1) TR200103819T2 (el)
UA (1) UA74782C2 (el)
WO (1) WO2000069441A1 (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
CA2428160C (en) * 2000-11-06 2009-10-13 Pharma Mar, S.A. Compositions for antitumor treatment containing ecteinascidin 743
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
IL161430A0 (en) * 2001-10-19 2004-09-27 Pharma Mar Sa Pharmaceutical compositions containing ecteinascidin 743
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
DK1689404T3 (da) * 2003-11-13 2009-01-26 Pharma Mar Sau Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
WO2005049030A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
WO2006005602A2 (en) * 2004-07-09 2006-01-19 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
NZ554765A (en) * 2004-10-26 2010-01-29 Pharma Mar Sa Pegylated Liposomal Doxorubicin In Combination With Ecteinescidin 743
ATE368461T1 (de) * 2004-10-29 2007-08-15 Pharma Mar Sa Zusammensetzungen enthaltend ecteinascidin und einen disaccharide
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
JP2009536956A (ja) * 2006-05-12 2009-10-22 ファルマ・マール・ソシエダード・アノニマ 抗癌治療法
AU2008313634A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Prognostic molecular markers for ET-743 treatment
WO2017133544A1 (zh) * 2016-02-04 2017-08-10 江苏恒瑞医药股份有限公司 一种曲贝替定的可注射胃肠外用药物组合物及其制备方法
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
CN112574234B (zh) * 2019-09-27 2022-05-24 江苏恒瑞医药股份有限公司 一种海鞘素衍生物的制备方法
EP4041194B1 (en) 2020-04-15 2024-03-13 EVER Valinject GmbH Composition comprising trabectedin and an amino acid
US20230226051A1 (en) 2022-01-20 2023-07-20 Extrovis Ag Trabectedin composition

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987007610A2 (en) * 1986-06-09 1987-12-17 University Of Illinois Ecteinascidins 729, 743, 745, 759a, 759b and 770
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
DE3635711A1 (de) 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
GB8805268D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
GB9101221D0 (en) * 1991-01-19 1991-02-27 Smithkline Beecham Plc Pharmaceuticals
US5721352A (en) 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5891704A (en) * 1992-11-19 1999-04-06 Anticancer, Inc. Method to produce high levels of methioninase
WO1994026250A1 (en) * 1993-05-14 1994-11-24 Depotech Corporation Method for treating neurological disorders
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
GB9508195D0 (en) 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
DK1586322T3 (da) * 1996-11-05 2008-12-01 Childrens Medical Center Sammensætninger indeholdende thalidomid og dextamethason til behandling af cancer
IL123740A0 (en) * 1997-03-28 1998-10-30 Pfizer NK-1 receptor antagonists for the treatment of delayed emesis
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
RU2217432C2 (ru) 1998-04-06 2003-11-27 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс Эктеинасцидины, фармацевтическая композиция, содержащая их и способ лечения опухолей
NZ508585A (en) * 1998-05-11 2002-11-26 Pharma Mar S Metabolites of ecteinascidin 743
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
WO2001077115A1 (en) 2000-04-12 2001-10-18 Pharma Mar, S.A. Antitumoral ecteinascidin derivatives
US7247892B2 (en) 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
CA2418320A1 (en) 2000-08-11 2002-02-21 City Of Hope The anti-neoplastic agent et-743 inhibits trans activation by sxr
CA2428160C (en) 2000-11-06 2009-10-13 Pharma Mar, S.A. Compositions for antitumor treatment containing ecteinascidin 743
WO2002064843A1 (en) 2001-02-09 2002-08-22 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
EP1372658A2 (en) 2001-03-30 2004-01-02 Shire Biochem Inc. Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
IL161430A0 (en) 2001-10-19 2004-09-27 Pharma Mar Sa Pharmaceutical compositions containing ecteinascidin 743
US20040019027A1 (en) 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
DK1689404T3 (da) 2003-11-13 2009-01-26 Pharma Mar Sau Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
WO2005049030A1 (en) 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
WO2006005602A2 (en) 2004-07-09 2006-01-19 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
EP1812114A2 (en) 2004-09-29 2007-08-01 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti-inflammatory agents
NZ554765A (en) 2004-10-26 2010-01-29 Pharma Mar Sa Pegylated Liposomal Doxorubicin In Combination With Ecteinescidin 743
ATE368461T1 (de) 2004-10-29 2007-08-15 Pharma Mar Sa Zusammensetzungen enthaltend ecteinascidin und einen disaccharide
CA2630900A1 (en) 2005-11-25 2007-05-31 University Of Medicine And Dentistry Of New Jersey Use of parp-1 inhibitors
JP2009536956A (ja) 2006-05-12 2009-10-22 ファルマ・マール・ソシエダード・アノニマ 抗癌治療法

Also Published As

Publication number Publication date
CY1105818T1 (el) 2011-02-02
BR0010531A (pt) 2002-06-04
DE60030554T2 (de) 2007-09-13
AU4597500A (en) 2000-12-05
WO2000069441A1 (en) 2000-11-23
LU91418I2 (fr) 2008-05-13
DK1176964T3 (da) 2007-01-15
PL352931A1 (en) 2003-09-22
SI1702618T1 (sl) 2008-02-29
CY1112753T1 (el) 2016-02-10
EP1176964B8 (en) 2007-10-10
KR20020019914A (ko) 2002-03-13
EP1716853A3 (en) 2006-11-15
UA74782C2 (uk) 2006-02-15
NO20015516L (no) 2002-01-11
AU2005200180B2 (en) 2007-12-13
NZ515423A (en) 2004-04-30
MY164077A (en) 2017-11-30
PT1716853E (pt) 2011-05-12
IL146434A (en) 2008-03-20
CY2008007I1 (el) 2009-11-04
HU229866B1 (en) 2014-10-28
CY2008007I2 (el) 2009-11-04
CA2373794C (en) 2005-10-11
ATE375795T1 (de) 2007-11-15
HUP0201187A3 (en) 2002-11-28
CN1679631A (zh) 2005-10-12
NL300337I1 (nl) 2008-05-01
ATE500830T1 (de) 2011-03-15
DE60030554T8 (de) 2008-01-10
HUP0201187A2 (en) 2002-09-28
AR028476A1 (es) 2003-05-14
PT1702618E (pt) 2008-01-11
EP1176964B1 (en) 2006-09-06
PT1176964E (pt) 2007-01-31
SI1716853T1 (sl) 2011-10-28
ES2294756T3 (es) 2008-04-01
AU777417B2 (en) 2004-10-14
EP1702618A3 (en) 2006-12-27
EP1702618B1 (en) 2007-10-17
DK1702618T3 (da) 2008-02-25
FR08C0013I2 (fr) 2009-10-30
EP1716853B9 (en) 2011-09-28
JP2012149095A (ja) 2012-08-09
HUS1500001I1 (hu) 2016-08-29
LU91418I9 (el) 2019-01-02
NO20015516D0 (no) 2001-11-12
US20070275942A1 (en) 2007-11-29
SI1176964T1 (sl) 2007-02-28
DE60045720D1 (de) 2011-04-21
AU2005200180B9 (en) 2008-05-29
CZ301482B6 (cs) 2010-03-17
PL198185B1 (pl) 2008-06-30
AU2005200180A1 (en) 2005-02-10
ATE338552T1 (de) 2006-09-15
DE60030554D1 (de) 2006-10-19
FR08C0013I1 (el) 2008-05-30
CZ20014081A3 (cs) 2002-11-13
NO324564B1 (no) 2007-11-19
EP1716853A2 (en) 2006-11-02
NL300337I2 (nl) 2008-09-01
EP1176964A1 (en) 2002-02-06
NO2008005I2 (el) 2010-09-27
DK1716853T3 (da) 2011-06-27
IL146434A0 (en) 2002-07-25
SK16442001A3 (sk) 2002-03-05
CA2373794A1 (en) 2000-11-23
CN1360503A (zh) 2002-07-24
DE60036826T2 (de) 2008-08-28
DE122008000013I1 (de) 2008-08-07
JP2002544231A (ja) 2002-12-24
TR200103819T2 (tr) 2002-04-22
EP1716853B1 (en) 2011-03-09
EP1702618A2 (en) 2006-09-20
US8119638B2 (en) 2012-02-21
NO2008005I1 (no) 2008-06-09
BG106171A (en) 2002-06-28
ES2272279T3 (es) 2007-05-01
JP5777562B2 (ja) 2015-09-09
CN100477993C (zh) 2009-04-15
MXPA01011562A (es) 2002-07-30
SK287580B6 (sk) 2011-03-04
BG65680B1 (bg) 2009-06-30
DE60036826D1 (de) 2007-11-29

Similar Documents

Publication Publication Date Title
CY1107143T1 (el) Χρηση του et743 στην συνδυαστικη θεραπεια με δεξαμεθαζονη για την θεραπευτικη αγωγη του καρκινου
WO2004052238A3 (en) Phototherapy bandage
DE60329509D1 (de) Behandlung von wirbelmetastasen
GEP20094798B (en) (s,s)-reboxetine for treating chronic pain
CY1108629T1 (el) Συνδυασμος ετ 743 με 5 φθοριοουρακιλο προ-φαρμακα δια την θεραπευτικη αγωγη του καρκικου
BR0107705A (pt) Uso de uma alìquota de sangue modificado em um paciente para tratamento de falência cardìaca congestiva
NO20032027D0 (no) Effektive antitumorbehandlinger
NZ544472A (en) Compounds and therapeutical use thereof
DE50004178D1 (de) Therapiebandage
CY1105564T1 (el) Θεραπεια συνδυασμου για καρκινο
ATE300262T1 (de) Allzweck -medikament und -wärmebehandlungssystem
WO2000040229A3 (en) Synergistic tumorcidal response induced by histamine
GB0020504D0 (en) Therapeutic method
BR0009380A (pt) Tratamento de câncer melhorado comtemozolomida
FI973185A0 (fi) Melatoniinin käyttö lääkeriippuvuudesta kärsivien potilaiden hoitoon
ES2058161T3 (es) Producto activo para la lucha contra tumores.
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
DK1150981T3 (da) Terapeutisk necleosidforbindelse
UA40393A (uk) Спосіб лікування хронічного обструктивного бронхіту
UA37041A (uk) Спосіб стимуляції функціональної активності т-лімфоцитів
RU94021815A (ru) Способ лечения злокачественных новообразований